Name:

Tilmicosin Premix

Common Capacity:

• 100g/bag
• 500g/bag
• 1000g/bag (1kg/bag)
• 5kg/bag
• 10kg/bag

Common Concentration:

• 10%
• 20%

Applicable Animals:

Tilmicosin is a macrolide antibiotic with strong inhibitory effects on Mycoplasma, Haemophilus, Pasteurella, Streptococcus, Staphylococcus, and various other sensitive bacteria in pigs and poultry. Its characteristic feature is a high affinity for respiratory system tissues, allowing rapid distribution to the lungs and maintaining high concentrations for extended periods. It is primarily used for the treatment and prevention of respiratory infections in livestock and poultry.

Applicable Animals in Global Animal Husbandry:

• Pigs: Primarily used for the treatment and prevention of porcine enzootic pneumonia (mycoplasmal pneumonia), contagious pleuropneumonia, swine streptococcosis, Haemophilus parasuis disease, and other respiratory diseases.
• Poultry (Chickens, Turkeys): Primarily used for the treatment and prevention of chronic respiratory disease (CRD), infectious coryza, and infections caused by Mycoplasma and Pasteurella, including airsacculitis.
• Cattle (Calves): Used for the treatment and prevention of respiratory diseases (such as shipping fever, calf pneumonia) caused by Mycoplasma bovis, Pasteurella, etc.

Usage and Dosage:

Tilmicosin premix is typically administered by mixing with feed. The product should be thoroughly mixed with feed before feeding. The dosage should be determined based on product concentration, animal species, body weight, and severity of the condition.

Mixed with Feed:

• Pigs:
  • For treatment of swine respiratory diseases (e.g., mycoplasmal pneumonia, contagious pleuropneumonia): 15-20 mg Tilmicosin per kg body weight, for 7-14 consecutive days.
  • Conversion to feed additive amount (for 10% product): Add 150-200g per 1000kg of feed.
• Poultry (Chickens, Turkeys):
  • For treatment of Mycoplasma disease, chronic respiratory disease: 15-20 mg Tilmicosin per kg body weight, for 3-5 consecutive days.
  • Conversion to feed additive amount (for 10% product): Add 150-200g per 1000kg of feed.
• Cattle (Calves):
  • For treatment and prevention of respiratory diseases: 12.5 mg Tilmicosin per kg body weight, once daily, for 3-5 consecutive days. It is recommended to calculate based on per ton of feed.

Dosage by Growth Stage:

• Piglets/Nursery Pigs: During weaning or the nursery period, due to stress, environmental changes, and increased density, respiratory diseases are highly common. It can be added at preventive or therapeutic doses.
• Growing-Finishing Pigs: Used to control enzootic pneumonia, contagious pleuropneumonia, etc., to reduce morbidity and mortality, and improve growth performance.
• Breeding Poultry: Can be used for the control and eradication of vertical transmission of Mycoplasma.

Applicable Diseases and Symptoms:

Tilmicosin is primarily used for the treatment of diseases caused by sensitive bacteria and Mycoplasma:

• Pigs:
  • Respiratory System Diseases: Porcine enzootic pneumonia (coughing, wheezing, stunted growth, reduced feed intake), contagious pleuropneumonia (high fever, dyspnea, hemoptysis, cyanosis), swine streptococcosis (manifested as respiratory symptoms or septicemia), Haemophilus parasuis disease (fibrinous polyserositis and Glasser’s disease).
• Poultry:
  • Respiratory System Diseases: Chicken chronic respiratory disease (sneezing, coughing, nasal discharge, airsacculitis), infectious coryza, avian mycoplasmosis.
• Cattle (Calves):
  • Respiratory System Diseases: Shipping fever, calf pneumonia (elevated temperature, coughing, dyspnea, nasal discharge), caused by Pasteurella species, Mycoplasma species, etc.

Precautions:

• Cardiotoxicity: Tilmicosin may cause cardiotoxicity in animals, especially equids and non-human primates, which are highly sensitive and should not be administered the drug. Pigs, cattle, and poultry may also exhibit cardiotoxicity at very high doses, potentially leading to death if used improperly.
• Cross-resistance: Cross-resistance exists between Tilmicosin and other macrolides and lincosamides.
• Drug Interactions: Avoid concomitant use with beta-lactam antibiotics (e.g., penicillin), as antagonism may occur.
• Withdrawal Period: Strict adherence to the product’s specified withdrawal period is necessary to ensure drug residues in animal products (meat, eggs, milk) comply with food safety standards.
• Homogenous Mixing: The premix must be thoroughly mixed with feed to ensure accurate drug intake by animals.
• Oral Administration: Oral administration of Tilmicosin is relatively safer than injection, with fewer toxic reactions.
• Storage: Store sealed in a cool, dry, well-ventilated place, away from direct sunlight.

Contraindications:

• Contraindicated in equids and non-human primates.
• Contraindicated in animals with a known hypersensitivity to macrolide drugs.
• Contraindicated in lactating dairy cattle.
• Contraindicated in laying hens.

Post-Administration Care:

• Observe Animal Status: Closely monitor the animal’s mental state, feed and water intake, respiratory condition, and fecal consistency during and after medication to assess treatment efficacy and detect any adverse reactions. Pay particular attention to signs of cardiotoxicity such as abnormal heart rate or rapid breathing.
• Improve Husbandry Environment: Maintain a clean, hygienic, appropriately temperate, and well-ventilated breeding environment to reduce dust and harmful gases, aiding in the recovery from respiratory diseases.
• Biosecurity Management: Enhance isolation and disinfection of sick animals to prevent disease spread.
• Supportive Therapy: For severely ill animals or those with complications, combine with other symptomatic and supportive therapies, such as vitamin supplementation, electrolytes, and antipyretics.
• Withdrawal Period Enforcement: Strictly record medication administration and discontinuation times to ensure that the animal is marketed only after the specified withdrawal period.